ertapenem has been researched along with Shock, Septic in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Holmes, AH; Nasomsong, W; Panuvatvanich, B; Rawson, TM; Vasikasin, V | 1 |
| Bauer, M; Claus, RA; Doulias, T; Giamarellos-Bourboulis, EJ; Kontopoulou, K; Koutelidakis, IM; Quickert, S; Weis, S | 1 |
| Gong, S; Hu, X; Jiang, Y; Li, J; Shang, X; Yu, R; Zhang, X; Zhang, Y | 1 |
| Chowers, M; Krashin, E; Lishner, M; Reisfeld, S | 1 |
| Fernández, L; Gómez-Rice, A; Lillo, M; Maseda, E; Ramasco, F; Villagrán, MJ | 1 |
| Cirioni, O; Della Vittoria, A; Ghiselli, R; Giacometti, A; Licci, A; Mocchegiani, F; Orlando, F; Saba, V; Scalise, G; Silvestri, C | 1 |
1 trial(s) available for ertapenem and Shock, Septic
| Article | Year |
|---|---|
[Septic shock due to community-acquired complicated intra-abdominal infection treated with ertapenem: outcome in 25 cases].
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactams; Cohort Studies; Community-Acquired Infections; Critical Care; Emergencies; Ertapenem; Female; Hospital Mortality; Humans; Intestinal Perforation; Length of Stay; Male; Middle Aged; Peritonitis; Prospective Studies; Shock, Septic; Survival Analysis; Treatment Outcome | 2008 |
5 other study(ies) available for ertapenem and Shock, Septic
| Article | Year |
|---|---|
Towards optimizing carbapenem selection in stewardship strategies: a prospective propensity score-matched study of ertapenem versus class 2 carbapenems for empirical treatment of third-generation cephalosporin-resistant Enterobacterales bacteraemia.
Topics: Adult; Anti-Bacterial Agents; Bacteremia; Carbapenems; Cephalosporins; Ertapenem; Escherichia coli; Humans; Propensity Score; Prospective Studies; Shock, Septic | 2023 |
Low-dose hydrocortisone prolongs survival in a lethal sepsis model in adrenalectomized rats.
Topics: Administration, Intravenous; Adrenalectomy; Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents; Cytokines; Disease Models, Animal; Drug Therapy, Combination; Ertapenem; Escherichia coli; Hydrocortisone; Immune Tolerance; Immunity, Innate; Liver; Male; Rats; Rats, Wistar; Shock, Septic; Treatment Outcome; Tumor Necrosis Factor-alpha | 2018 |
Clinical Situations of Bacteriology and Prognosis in Patients with Urosepsis.
Topics: Ertapenem; Escherichia coli; Gram-Negative Bacterial Infections; Humans; Imipenem; Klebsiella pneumoniae; Quinolones; Sepsis; Shock, Septic; Urinary Tract Infections | 2019 |
Candida albicans in peritoneal fluid in a patient with hepatic encephalopathy.
Topics: Administration, Intravenous; Anti-Bacterial Agents; Antifungal Agents; Ascites; Ascitic Fluid; beta-Lactams; Candida albicans; Ertapenem; Escherichia coli; Escherichia coli Infections; Fatal Outcome; Female; Fluconazole; Hepatic Encephalopathy; Hepatitis C; Humans; Liver Cirrhosis; Middle Aged; Paracentesis; Shock, Septic | 2014 |
The cathelicidin-derived tritrpticin enhances the efficacy of ertapenem in experimental rat models of septic shock.
Topics: Animals; Anti-Bacterial Agents; Antimicrobial Cationic Peptides; beta-Lactams; Cathelicidins; Cecum; Disease Models, Animal; Drug Synergism; Endotoxins; Enterococcus faecalis; Ertapenem; Escherichia coli; Escherichia coli Infections; Interleukin-6; Ligation; Male; Microbial Sensitivity Tests; Oligopeptides; Rats; Rats, Wistar; Shock, Septic; Tumor Necrosis Factor-alpha | 2006 |